We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Expanded Steroid Control Launched at the 2015 AACC Annual Meeting

By LabMedica International staff writers
Posted on 30 Jul 2015
The SMx Serum Specialty Matrix Control Sample
The SMx Serum Specialty Matrix Control Sample (Photo courtesy of UTAK LABORATORIES)
Expanded Steroid Control has been launched that now contains nine analytes of interest at clinically relevant levels for mass spectrometry and separation science technology.

The nine analytes included in the specialty matrix are Corticosterone, Cortisol, Cortisone, Dehydroepiandrosterone (DHEA), Progesterone, 17α-Hydroxyprogesterone, Testosterone, with the addition of Androstenedione and 11 Deoxycortisol.

The Expanded Steroid Control is manufactured by UTAK (Valencia, CA, USA) within its proprietary SMx Serum Specialty Matrix. For use with any methodology, UTAK's stock and custom quality controls are handcrafted and sold to Clinical, Toxicology and Esoteric laboratories globally. UTAK's Expanded Steroid Control in SMx Serum, is offered in individual packs for Levels 1, 2, 3, 4 and a Negative Control. The International Organization for Standardization (ISO) accreditation guidelines note that independent third party quality controls should be used instead of, or in addition to, any control materials supplied by the reagent or instrument manufacturer. UTAK offers hundreds of stock and custom serum, whole blood, urine and oral fluids controls for use with any methodology, on any testing platform.

Jim Plutchak, CEO of UTAK, said, “Our goal is always to craft Quality Controls for Clinical and Esoteric laboratories that are as close to a human matrix as possible. Due to the issue of endogenous steroid levels in serum-based matrix products, we developed a Steroids Control in our SMx Specialty Matrix. The result is a third party control that esoteric laboratories can depend on for their laboratory developed tests.” Charles E. Pippenger, PhD, adjunct professor Department of Neurosciences, University of Vermont College of Medicine added, “Inter-laboratory comparison of results, made possible with a uniform control, allows labs to be confident that test results generated are accurate.”

The Expanded SMx Steroid Control was released at the 2015 American Association of Clinical Chemistry (AACC) Meeting & Clinical Lab Expo held July 26–30, in Atlanta (GA, USA).

Related Links:
UTAK
University of Vermont College of Medicine 
American Association of Clinical Chemistry  


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Elevated creatinine levels do not necessarily indicate impaired kidney function: pre-treatment cystatin C measurement is key to assessment (Image Credit: Data panels adapted from Watanabe H, et al. Clin Pharmacol Ther (2026). All icons were obtained from bioicons.com and modified.)

Cystatin C Testing Helps Distinguish Abemaciclib Effect from Kidney Injury

Kidney function monitoring in breast cancer care often relies on serum creatinine, a routine blood marker used to estimate renal function. However, creatinine increases in patients receiving abemaciclib... Read more

Molecular Diagnostics

view channel
Image: These images show breast tumors in a new preclinical model developed by Garvan researchers. The cells carry a fluorescent sensor that lights up blue/green when CDK1—the protein \'engine\' cells need to divide—is switched on. Using it, the team watched CDK1 activity rise as tumors became invasive and stay high in tumors that kept growing despite treatment. (Image Credit: Dr. Max Nobis / Garvan Institute)

Study Finds Potential Marker of Targeted Drug Resistance in Breast Cancer

Estrogen receptor-positive breast cancer is the most common breast cancer subtype and is driven by estrogen. Many patients are treated with CDK4/6 inhibitors alongside hormone therapy, but these drugs... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: The test uses serum or plasma from patients with suspected acute infection and symptoms lasting fewer than seven days and generates a score indicating the likelihood of bacterial infection. (Image Credit: Shutterstock)

Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections

Bacterial and viral infections often cause similar symptoms, making early differentiation difficult in emergency and urgent care settings. Clinicians may need to begin treatment before traditional diagnostic... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more